Document is current
Any future updates will be listed below
-
Authors
Olivieri, Martin https://orcid.org/0000-0001-6434-6244
Yan, Songkai https://orcid.org/0000-0002-1677-3839
Yang, Ying
Tomic, Radovan
Linhoff, Thomas https://orcid.org/0000-0001-8210-9277
Zhang, Xiang
Drelich, Douglass https://orcid.org/0009-0004-7388-2013
Jakobs, Natalie
Miesbach, Wolfgang https://orcid.org/0000-0002-4506-0061
-
Funding
Funding for this research was provided by:
CSL Behring
- License Information
-
More Information
Article History
Received: 16 April 2025
Accepted: 31 July 2025
First Online: 18 September 2025
Declarations
:
: Martin Olivieri has received grants/research support from Bayer, Biomarin, Biotest, Takeda, CSL Behring Octapharma, Pfizer, Shire, Roche, Stago and Swedish Orphan Biovitrum, consultancy and speaker fees from Bayer, BioMarin, Biotest, Novo Nordisk, Takeda, CSL Behring, Pfizer, Roche and Swedish Orphan Biovitrum; Songkai Yan, Radovan Tomic, Xiang Zhang, Thomas Linhoff and Douglass Drelich are employees of CSL Behring; Ying Yang and Natalie Jakobs are employees of Adivo Associates; Wolfgang Miesbach received consultation fees from Bayer, BioMarin, Biotest, CSL Behring, Chugai, Freeline, LFB, Novo Nordisk, Octapharma, Pfizer, Regeneron, Roche, Sanofi, Sobi, Takeda/Shire, uniQure.
: Following institutional review board (IBR) evaluation, the study was determined to be exempt from patient informed consent under category 4 (IBR case name: CSL Behring - 2023-168, Patient chart analysis to assess real-world outcomes and utilisation of recombinant FIX products in Germany and Italy—IRB protocol#: [Pro00072842]) as secondary research for which consent is not required; this applied to all 31 haemophilia treatment centres involved in the study.
